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Abstract
Chronic hepatitis C (HCV) is a common infection affecting 185 million people worldwide. The most common
manifestation of chronic HCV is progressive liver fibrosis, cirrhosis, liver failure and hepatocellular carcinoma.
However, several systemic manifestations of HCV have been recognized and reported in the literature. The
purpose of this review is to assimilate published literature based on evidence to categorize these extrahepatic
manifestations with the likelihood of a causal association with HCV. Exciting recent developments have resulted in simple
all oral interferon-free highly effective therapy for HCV. However, this treatment is also expensive and less accessible to
most affected individuals as treatment recommendations are based on stage of liver fibrosis. Expanding the scope of HCV
therapy to those with extrahepatic manifestations beyond what is currently recommended will significantly reduce the
morbidity and mortality in this aging population.
Keywords: HCV, Cryoglobulinemia, Autoantibodies, Lymphoma
Background
Hepatitis C (HCV) is a single stranded RNA virus be-
longing to the family Flaviviridae and genus Hepacivirus
[1]. It preferentially infects hepatocytes and establishes a
chronic infection in approximately 85 % of patients with
acute infection [2]. Globally, over 185 million people are
affected by chronic HCV [2]. Chronic HCV infection
can lead to cirrhosis of the liver, liver failure and hepato-
cellular carcinoma, and is the most common cause of
liver transplantation in the USA and Western Europe
[2]. Highly effective, interferon-free, direct acting anti-
viral (DAA) agents for chronic HCV are now available,
resulting in sustained virologic response ([SVR], consid-
ered functional cure), for the majority of patients able to
access the medications. The high cost of DAA therapy
has resulted in prioritization of patients for therapy.
Prioritization is most frequently based on the stage of
liver disease; however, chronic HCV is actually a sys-
temic disease and is associated with several debilitating
extrahepatic manifestations that should be taken into
consideration for prioritization of HCV therapy. To date,
there has not been any correlation between the extent of
systemic symptoms and stage of liver disease. As a
result, these manifestations are often overlooked by pro-
viders when deciding who should benefit from the expen-
sive DAA therapy. This review focuses on categorizing the
clinical syndromes reportedly associated with chronic
HCV based on the strength of epidemiological evidence.
This approach will allow clinicians to prioritize therapy
for patients with extrahepatic symptoms.
Overview of HCV as a systemic disease
HCV is a hepatotropic virus; however, the chronic HCV
infection can result in global health impairment, with up
to 74 % of patients experiencing some form of extra-
hepatic manifestation [3]. These can be present long
before the stage of advanced liver disease and include
non-specific symptoms such as fatigue, nausea, abdom-
inal or musculoskeletal pain, loss of weight, and neuro-
psychiatric symptoms including depression, irritability
and malaise; and more specific biological manifestations
such as cryoglobulinaemia vasculitis, lymphoproliferative
disorders such as B-cell non-Hodgkin lymphoma, renal
disease, type II diabetes mellitus, cerebrovascular and
cardiovascular events, porphyria cutanea tarda and li-
chen planus. Table 1 summarizes the manifestation that
will be reviewed in this review, organized according to
the strengths of association with HCV. The importance
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of extrahepatic disease has been highlighted in a large
prospective natural history study from Taiwan. In this
study, 1095 patients positive for HCV antibody (AB)
were followed for a mean duration of 16 years and HCV
AB seropositivity was associated with increased non-
liver-related mortality: cumulative 18-year mortality due
to extrahepatic disease was 19.8 % compared to 11.0 and
12.2 % among those who spontaneously cleared their
HCV infection and those who never acquired HCV,
respectively. Multivariate–adjusted hazard ratio for non-
liver causes of death was 1.47 (95 % CI, 1.23–1.77)
among those who were HCV RNA positive, and chronic
HCV infection was associated with an increased (1.4-
fold) mortality from circulatory diseases [4]. Taken to-
gether, strong epidemiological data support that HCV as
a systemic disease, associated with significant extra-
hepatic morbidity.
The systemic benefits of HCV cure
Achievement of SVR has been shown to result in reduc-
tion in liver related and all cause mortality in several re-
cent studies. The non-liver related mortality was
significantly reduced in a large European cohort
followed for over 7 years after achieving SVR [5]. In the
United States, a large study conducted at the Veterans’
Administration also demonstrated lower non-liver re-
lated mortality attributable to HCV comorbidities such
as diabetes, hypertension and cardiovascular disease [6].
A third, multi-center study that followed patients with
SVR over 8.4 years also demonstrated a significant re-
duction in liver-related as well as all cause mortality [7].
More recently, Hsu et al. analyzed the effect of HCV
treatment on adverse outcomes (death, end stage renal
disease, ischemic stroke, and acute coronary syndrome)
among patients with HCV. The incidence of these
events were significantly lower among patients treated
for HCV [8], a benefit that was also demonstrated
among patients with co-existing diabetes mellitus [9].
These patients were treated with interferon-based ther-
apy. The impact of treatment on other extrahepatic
manifestations has not been as clearly demonstrated. We
anticipate that DAA therapy, with its improved efficacy
and anticipated wide ranging uptake, will allow the ben-
efits of SVR to be more readily characterized. Awareness
of clinicians to seek out and treat patients with HCV
comorbidities is key in achieving this goal.
The remainder of the review will focus on non-hepatic
diseases associated with chronic HCV infection. Table 1
summarizes the diseases reviewed. We will summarize
the evidence supporting their association with HCV,
including, if available, evidence of amelioration with
HCV clearance.
Manifestations most likely associated with chronic HCV
These are associated conditions that have the strongest
clinical prevalence data with chronic HCV [10, 11].
These include mixed cryglobulinemic syndrome (MCS)
and B cell non-Hodgkin’s lymphoma.
Mixed cryoglobulinemic syndrome MCS is a small to
medium vessel vasculitis characterized by the expansion
of B cells resulting in production of cryoglobulins: im-
mune complexes of polyclonal immunoglobulin (Ig) G
and monoclonal or polyclonal IgM with rheumatoid fac-
tor that precipitate at lower temperatures [12]. These fix
complement and lead to endothelial tissue damage and
vasculitis [10, 11]. The resulting syndrome can manifest
in skin, major joints, peripheral nerves, and renal dis-
ease. As high as 90 % of cases of MCS are associated
with chronic HCV [13]. Dermatological manifestations
are the most common with palpable purpura [10, 11].
Other manifestations include arthritis, non-healing ul-
cers, peripheral neuropathy, central nervous involve-
ment, and glomerulonephritis [10, 11]. The diagnosis is
confirmed by the presence of cryoglobulins, elevated
rheumatoid factor and immunofluorescence of comple-
ment fixing IgM in tissues.
Treatment of HCV-associate MCS may target HCV, or
the downstream B cell arm of autoimmunity. Until re-
cently, HCV therapy was dependent upon interferon and
mixed cryoglobulinemia is identified as a negative prog-
nostic factor of virologic response [14]. In a large pro-
spective study of HCV treatment with pegylated
interferon alpha among 253 patients with MCS or mixed
cryoglobulinemia (circulating cryoglobulins but without
MCS), 48.6 % achieved SVR. All but 2 of the 121 pa-
tients with MCS saw clinical-immunological resolution
Table 1 A summary of the extrahepatic Manifestations of
Hepatitis C discussed in this review
Extrahepatic manifestations
Most likely Associated with HCV
Mixed Cryoglobulinemic Syndrome
B-Cell Non-Hodgkins Lymphoma
Probably Associated with HCV
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at 6 month follow up. Among the patients with MCS
who did not achieve SVR, a transient improvement the
syndrome was seen in some patients by the end of treat-
ment; however, improvements did not persist at follow
up [14]. This study supports that of an earlier, smaller
study where HCV viral relapse occurred within 2 months
of follow up in 8 patients, 6 of whom also saw a relapse
in MCS [15]. The first generation NS3/4A protease in-
hibitors boceprevir and telaprevir were among the earli-
est DAA agents to be approved for HCV therapy. Triple
therapy with pegylated interferon, ribavirin, and telapre-
vir or boceprevir was studied among participants with
MCS in a pilot study. In this study, SVR rates were still
low despite addition of boceprevir with none of the 5
patients with MCS and only 5 out of 16 of patients with
mixed cryoglobulinemia without symptoms achieving
SVR [16]. In contrast, a more recent study of 30 patients
with MCS reported improved SVR (66.7 %) rates, with
70 % or patients achieving complete resolution of MCS
clinical parameter [17]. This regimen, however, was asso-
ciated with significant side effects. Newer DAA agents
have excellent tolerability, are highly effective when used
in combination, and do not require concurrent inter-
feron therapy for the vast majority of patients. Subse-
quently, triple therapy with the first generation protease
inhibitors is no longer recommended for HCV therapy.
There are few publications reporting the efficacy of
novel DAA therapy among patients with MCS. A case
report documents successful clinical response associated
with SVR in one patient with severe MCS after 12 weeks
of combination therapy with ombitasvir, paritaprevir, ri-
tonavir, and dasabuvir [18]. The VASCUVALDIC study
was a prospective study that treated 24 patients with
MCS with sofosbuvir and ribavirin. By end of treatment
87.5 % of patients had complete clinical response (im-
provement of all affected organs and absence of clinical
relapse). Cryoglobulin disappearance occurred in 46.1 %
of cases, and overall SVR was 74 %. Gragnani et al.
treated 17 (7 with mixed cryoglobulinemia, and 10 with
MCS) patients with interferon-free, DAA-based therapy
and report improvement in clinical parameters in all the
patients with MCS [19]. Sise et al. treated 12 patients
with HCV-associated MCS (including 7 with renal in-
volvement) with sofosbuvir (an NS5A inhibitor and the
backbone of most DAA-based therapies currently ap-
proved for use in USA and Europe) in combination with
either simeprevir (an NS3A/4A protease inhibitor) or
ribavirin. The majority of patients were treated with
12 weeks of therapy and overall SVR rate was 87 %. Six
of the patients with renal involvement achieved SVR,
and this was associated with improvement in renal func-
tion and reduction in proteinuria. Cryoglobulin levels at
follow up decreased for all patients compared to base-
line, except for one patient who experienced virological
relapse, with complete cryoglobulin loss in 4 of the 9 pa-
tients with levels available at follow up [20]. Importantly, 5
patients were on immunosuppression (4 with rituximab,
and1 with ustekinemab for psoriasis) while on HCV treat-
ment and several were able to reduce immunosuppression
with only 1 (who experienced virologic failure) requiring
increase in immunosuppression [20].
Several studies have supported the efficacy and safety of
rituximab—a monoclonal antibody against CD20 that re-
sults in B cell depletion—for the treatment of HCV-
associated MCS [21]. Only 2 prospective, randomized
controlled trials have been published so far, reporting suc-
cess in attaining remission and symptomatic relief [22]
and greater survival (64.3 % versus 3.5 %, P < 0.0001) at
month 12 [23] among patients who did not achieve SVR
with antiviral therapy or intolerant to interferon alpha and
ribavirin. A systemic review by Visentini et al. found that
32 % of patients experienced relapse after clinical response
after rituximab monotherapy [21]. The same authors con-
ducted a phase II study of low-dose rituximab for the
treatment of MCS and reported a 41 % relapse [21].
Therefore, the proportion of patients who relapse after
clinical response with rituximab monotherapy remains
sizeable, solidifying the need for virological treatment.
MCS is a multisystem disease with significant morbid-
ity. Current evidence supports the resolution of MCS for
most patients who are treated for HCV and achieve
SVR. Therefore, patients with mixed cryoglobulinemic
vasculitis should be prioritized for treatment with
current DAA-based therapy. It is expected that over
time, this syndrome will be occurring with lower
frequency.
B cell Non-Hodgkin’s Lymphoma (NHL) HCV is also
a lymphotropic virus and since 1994, B cell NHL has
been associated with chronic HCV infection [24]. It is
conceivable that B cell NHL is a progression of B cell ex-
pansion observed in mixed cryoglobulinemia as this con-
dition is often described as a precursor of NHL [25].
These patients are at much higher risk (about 35 times
more than the normal population) of developing NHL
[26]. Chronic antigenic stimulation of B cells result in a
monoclonal expansion of B cells (possibly mediated by
CD81 engagement) gaining oncogenic potential over
time [27]. A meta analysis of 15 studies suggested in
countries where HCV AB seropositivity is high, about
one-tenth of all NHL are attributable to chronic HCV
infection [28]. A retrospective study comparing patients
with HCV and not treated with patients who received
interferon therapy found that the cumulative rates of
malignant lymphoma (including diffuse large cell and
follicular lymphoma) was 0.62 % at the end of the 5th
year, 2.26 % at the 10th year, and 2.62 % at the 15th year.
This did not differ among those who did not respond to
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interferon therapy. Importantly, among patients who
were successfully treated of HCV, cumulative rate of
lymphoma was 0 % at all timepoints up to 15 years [29].
This is further supported by observations of remission of
NHL and a positive impact on survival with HCV treat-
ment of HCV [30–33]. Literature reporting the outcome
of HCV treatment with interferon-free, novel DAA-
based therapy is currently still limited to case reports.
These report regression of lymphoma with successful
HCV treatment [34–37]. As DAA-based HCV therapy
becomes more widely used, the results from larger co-
horts will hopefully be reported.
Manifestations likely associated with chronic HCV
These are clinical symptoms and disease manifestations
that occur at higher frequency in chronic HCV than
general population, although clinical association is not
supported by strong epidemiological data.
Diabetes mellitus type 2 Several studies have demon-
strated that chronic HCV is associated with a high
prevalence of insulin resistance [38, 39] and diabetes
mellitus [38, 40]. Patients with chronic HCV have a 2.3
fold increased chance of having type 2 diabetes mellitus
[41]. HCV-infected Huh 7.5 cells expressed higher levels
of peroxisome proliferator-activated receptor-gamma co-
activator alfa (PGC1-alfa) and glucose production [42].
Diabetes mellitus has also been shown to alter the
course of chronic HCV infection by contributing to a
proinflammatory intrahepatic microenvironment
resulting in accelerated liver fibrogenesis [43]. In a
retrospective study of 21 patients with chronic HCV
and type 2 diabetes mellitus treated with interferon-free
DAA-based therapy, mean glucose significantly decreased
during treatment (mean decrease −52.86 mg/dl, p = 0.007).
In this study, hemoglobin A1C values were available for 10
patients, and were reduced in 8 (mean reduction −1.95 %,
p = 0.021) [44]. Further, larger studies are needed to con-
firm the association between type 2 diabetes mellitus and
chronic HCV, and the prioritization of these patients for
HCV treatment.
Membranoproliferative glomerulonephritis Chronic
HCV is associated with multiple renal abnormalities, but
membranoproliferative glomerulonephritis (MPGN) as-
sociated with cryoglobulinemia is the most common
[45]. Non-cryoglobulinemic MPGN, IgA nephropathy,
post-infectious glomerulonephritis, and focal and seg-
mental glomerulosclerosis have been described in
chronic HCV patients. Although cryoglobulins are ob-
served in more than half of all chronic HCV patients,
approximately 1 % of these patients develop mixed cryo-
globulinemic vasculitis with end organ damage [46]. Pa-
tients with mixed cryoglobulinemic vasculitis usually
manifest with mild to moderate renal insufficiency as
well as microscopic proteinuria and hematuria. Renal bi-
opsy of these patients usually shows classic MPGN with
immune complex deposition in the glomeruli [47]. Ther-
apy for HCV MPGN is oriented at the immune response
and eradication of HCV. HCV therapy is usually associ-
ated with improvement or resolution of renal and der-
matological manifestations of mixed cryoglobulinemic
vasculitis [48]. The goal is to treat HCV with newer
DAA agents that would result in improved renal
function.
Neurological impairments Involvement of the central
nervous system in chronic hepatitis is an intense area of
investigation. It is hypothesized that the effect of HCV
on the brain is likely to be a direct infection with indir-
ect stimulation of neurotoxic cytokines and development
of CNS vasculitis. Approximately half of all HCV pa-
tients report some degree of impaired neurocognition
[49, 50]. Imaging studies of the brain in patients with
chronic HCV demonstrate vascular changes that could
explain some of the defects in cognitive function ob-
served [51]. Whether HCV actively replicates in the
brain is an area of intense debate. Studies have demon-
strated HCV RNA and negative strand RNA in brain tis-
sue and cerebrospinal fluid suggesting active HCV
replication in the CNS [52, 53]. Similarly, HCV proteins
have also been detected in astrocytes by immunohisto-
chemistry, although this is not necessarily representative
of direct infection [54]. Indirect activation of monocytes
by engaging toll-like receptor 2 on dendritic cells has
also been suggested as a potential mechanism for HCV
neurotoxicity [55]. Recently, post mortem studies of
brain tissue of patients with HIV and HCV indicate a
strong independent association of HCV and not HIV to
small-vessel cerebrovascular disease [56].
Advanced liver disease by itself can affect neurocogni-
tive function independent of HCV status. These patients
develop porto-venous shunts that transport neurotoxic
products directly to the systemic circulation. One hy-
pothesis for the neurocognitive impairment associated
with advanced liver disease is that neurotoxins such as
ammonia may then cross the blood brain barrier [11].
Increased permeability of the blood brain barrier to am-
monia [57] and increased brain uptake and utilization of
ammonia among patients with hepatic encephalopathy
compared to those without has been demonstrated [58].
More studies are required to clarify an independent as-
sociation of HCV infection on neurological impairment
independent of that occurring as a result of underlying
liver fibrosis. HCV has also been associated with periph-
eral neuropathy with both sensory and motor impair-
ment. It is likely that mixed cryoglobulinemic vasculitis
may explain this phenomenon in some patients, while
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many without cryoglobulinemic vasculitis also have per-
ipheral neurological symptoms.
Sicca syndrome Sicca syndrome occurs in most patients
with Sjogrens’ syndrome. Several host factors contribute
to the development of Sjogren’s syndrome and chronic
HCV has also been implicated as one of the causative
factors [59]. It is unclear if HCV is truly a causative
agent of, or whether patients with HCV present with
clinical symptoms that mimic sicca syndrome. Although
histologically similar, HCV associated sicca syndrome
presents at a later age in men along with elevated serum
cryoglobulins and rheumatoid factor, low serum comple-
ment, positive antinuclear antibody and negative Ro/La
[60]. Treatment of chronic HCV results in resolution of
symptoms in patients with sicca syndrome [61].
Porphyria cutanea tarda Porphyria cutanea tarda
(PCT) is the most common of the porphyrias and is as-
sociated with chronic HCV infection [62]. The biochem-
ical abnormality that manifests as PCT is the decreased
activity of the enzyme uroporphyrinogen decarboxylase
[63]. Associated clinical conditions such as iron over-
load, alcohol abuse, and estrogens accentuate the symp-
toms of PCT [62]. Almost half of all PCT patients have
chronic HCV infection, while PCT occurs in 1–5 % of
all patients with chronic HCV [64]. We still do not
completely understand the underlying mechanisms in-
volved in this association. In general, treatment for HCV
is associated with normalized enzymatic activity, ALT
levels, urine porphyrins and skin lesions [65]. It is
unclear if the new emergent DAA therapy will have an
impact on this peculiar biochemical abnormality ob-
served in HCV patients.
Lichen planus Lichen planus is a chronic mucocutane-
ous disease of inflammatory origin. The common areas in-
volved include limbs, face, scalp, nails and mucosal
surfaces in gastrointestinal and genitourinary tracts [66].
Approximately 10–23 % of patients with chronic HCV
manifest lichen planus [67]. It is likely that the underlying
mechanism for the higher prevalence of lichen planus is
immune related. Recent studies have reported shared pep-
tide homology between HCV and desmoglein-3 as a po-
tential antigenic mimicry mechanism for lichen planus
[68]. Treatment of HCV with interferon-based therapy
has not resulted in a resolution of lichen planus in most
studies [69, 70], leaving providers without an optimal
treatment regime for the management of patients with
HCV and lichen planus.
Manifestations possibly associated with chronic HCV
These include several clinical syndromes that have been
reported to occur at a higher frequency in patients with
HCV. The clinical data that support each situation are
primarily from case reports or case series rather than
controlled studies. Hence, it is unclear to establish a dir-
ect causative role for HCV and these clinical syndromes.
Thyroid abnormalities Thyroid abnormalities are more
commonly reported with HCV infected patients in rela-
tion to interferon-alfa treatment. Approximately 15 % of
all patients receiving interferon-alfa based HCV therapy
will report clinical thyroid dysfunction. Interestingly,
more than 35 % of these patients also develop thyroid
autoantibodies. The mechanism for these includes an
autoimmune phenomenon induced by immune-based
therapy, which are often persistent even after discon-
tinuation of therapy. Several studies have also associated
the presence of abnormal thyroid autoantibodies in ap-
proximately one-tenth of all patients with chronic HCV
prior to initiation of therapy [71]. Some investigators
have detected HCV RNA in thyroid tissues, while others
have productively infected thyroid cell lines with HCV.
The authors hypothesize that HCV infection of thyro-
cytes could result in a localized inflammatory response
and initiate autoimmune injury [72, 73]. All HCV pa-
tients should be screened for thyroid dysfunction and
treated appropriately. Some clinicians also monitor those
with abnormal autoantibodies closely for development of
thyroiditis and symptoms. It will be interesting to see if
eradication of HCV without the use of interferon-alfa
using new DAA agents should ameliorate thyroid dys-
function in patients with HCV.
Autoantibodies Circulating autoantibodies are high in
patients with chronic HCV when compared to normal
individuals. Mostly, these include cryoglobulins (60 %),
rheumatoid factor (60 %), antinuclear antibody (40 %),
antithyroid (35 %), anticardiolipin (15 %), and anti-
smooth muscle antibodies (7 %) [3]. Alarmingly, half of
all patients with chronic HCV present with at least one
immunological abnormality [3]. None of these autoanti-
bodies are associated with clinical abnormalities except
for mixed cryoglobulins.
Mooren’s corneal ulcers Several studies have associated
rare ocular syndromes such as Mooren’s ulcer with HCV
infection [74]. HCV infection is associated with several
ocular conditions including keratitis, sicca syndrome
likely from reduced lacrimation. Mooren’s ulcer is a rare,
painful peripheral corneal ulceration usually manifesting
without any associated scleritis [74]. The pathogenesis of
this phenomenon in HCV patients is not completely
understood. HCV infection is also associated with
episcleritis, retinal vasculitis and retinopathy and in-
creased intra ocular pressures compared to the general
population [75, 76].
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Cardiovascular events Chronic HCV is associated with
accelerated atherogenesis [77]. A systematic review
found that the risk of developing early carotid artery
atherosclerosis (measured by intima-media thickness)
and the risk of advanced atherosclerosis (measured by
the detection of carotid artery plaques) were about
four times higher among patients with HCV compared
to non-infected patients [78]. Several HCV cohorts
have also reported an increase in cardiovascular dis-
ease related mortality [79], including a large cohort of
over 10,000 HCV antibody positive blood donors,
among whom there was a 2 fold increase in cardiovas-
cular mortality (HR = 2.21, 95 % CI: 1.41, 3.46) com-
pared to HCV antibody negative donors [80]. It is
unclear why there is an increased risk of vascular
events in patients with chronic HCV, but it is plausible
that underlying proinflammatory cytokines present at
high levels in patients could contribute to a proathero-
genic milieu. Interestingly, a recent study reported
greater endothelial dysfunction and increased carotid
intima medial thickness among patients with genotype
1 infection compared with non-genotype 1 infection
suggesting genotypic differences in vascular risk [81].
Furthermore, since the presence of diabetes mellitus is
also increased among patients with chronic HCV, this
could contribute as a significant co-factor in accelerat-
ing cardiac events. As the HCV-infected population
ages, the risk of cardiac events also increases consider-
ably. In a recent large study, treatment of HCV with
interferon and ribavirin was associated with a 23 and
38 % reduction in acute coronary syndrome and ische-
mic stroke over an 8-year study period [8]. The recent
development of DAA therapy would permit expanded
treatment of patients to reduce the cardiovascular
morbidity and mortality.
Conclusions
Chronic HCV is associated with multi-system manifesta-
tions beyond the liver. In general, the occurrence of
these manifestations is unpredictable and occurs irre-
spective of the stage of the liver disease. Recent develop-
ments in HCV therapeutics have established simpler, all
oral, highly effective DAA agents as first line of treat-
ment [82]. The high cost of DAA therapy has resulted in
treatment being reserved for patients with the most ad-
vanced liver fibrosis [83]. A careful examination for ex-
trahepatic manifestations in chronic HCV patients is
warranted to prioritize HCV therapy for these individ-
uals, since eradication of HCV is often associated with
cessation of extrahepatic manifestations. Expanding the
treatment to all those who have extrahepatic symptoms
could improve the morbidity and mortality associated
with systemic HCV disease.
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